NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

NMIBC management includes TURBT and intravesical therapy, with BCG as a key treatment for higher-risk patients.
BCG treatment stimulates an immune response, enhancing the body's ability to target bladder cancer cells.
Ideal BCG treatment outcomes focus on minimizing recurrence and progression in high-risk NMIBC patients.
Discrepancies exist between real-world progression rates and clinical practice, emphasizing personalized treatment approaches.

Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

Now Viewing

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What are the standard treatment options for non–muscle-invasive bladder cancer (NMIBC)?

What are the management options for patients with intermediate and high-risk NMIBC?

Can you explain the mechanism of action of BCG treatment in stimulating the immune response against bladder cancer?
In an ideal treatment paradigm with single-agent BCG, what are the best outcomes for patients with high-risk NMIBC?

What are the rates of recurrence and progression?
What do you feel the rates of progression are in the real world vs what you see in your practice?